Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-week open-label flexible-dose fesoterodine study in overactive bladder
2008-004124-23Phase 4Completed
- Sponsor
- Pfizer
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fesoterodine in overactive bladder (OAB), sponsored by Pfizer. Primary endpoint: Change in mean number of micturitions per 24 hours at Week 12 relative to baseline. Started Jan 2009; status: completed.
02
Drugs
fesoterodine
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2008-004124-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004124-23.